PEPTIDE

# Semax

Heptapeptide ACTH(4-10) analog; upregulates BDNF and NGF in CNS without HPA-axis activation. Approved in Russia for stroke and cognitive indications.

BIOGATE · GREEN | POSTERIOR 48.2% | MW 813.9 | 7AA

**SEQUENCE**

MEHFPGP

Modifications: intranasal formulation; ACTH(4-7) analog

## PDA-V1 chain of custody

Outer hash

3-d0c43ca3e0c455d3b0c40a43c0c4237390c3d7e3a0c3f11370c3a58

Merkle root

9296-a64d9196a4ba9096a3278f96a1948e96a0018d969e6e8c969cdb8b969b48

Inputs

7431-cd4a7531cedd7231ca247331cbb77031c6fe7131c8916e31c3d86f3

TEE attestation

38-e537e737e536543ae53b0d39e5397a34e5319b33e5300836e534c135e5332e

## Living Outcome Oracle

± =57.9 ² =62.1 **P(success) = 48.2%** 95% CI [36.2%, 60.2%]

## Seven-rule export gate

6 / 7 rules satisfied · audience: researcher · Full attestation set, raw posteriors, all hashes

- Grade A or B citation present on the core claim
- BioGate verdict is GREEN or AMBER (RED/BLACK refused)
- Jurisdiction permits the audience-appropriate use
- RWE summary attached when claim depends on outcome data
- Prediction-outcome pairs disclosed when posterior cited
- No human-use claim beyond cited indications
- COA registry lookup available for any synthesis claim

**BLOCK REASONS**

Grade A or B citation present on the core claim

## Citations

GRADE C

2002 · Bull Exp Biol Med

**Behavioral effects of Semax during chronic intranasal administration**

Levitskaya NG et al.

PMID 12298829